@DerickBores@CueBiopharma Also Siddhartha needs to be COO, only his operational excellence can uplift this company. I can't understand why is he so underutilized? @DerickBores you seem to know about Cue, do you have any idea what is Siddhartha doing there?
@WallStreetApes Dude if they are on H1-B, their motherland is India. What kind of stupid question is that. Yes, I do agree we need to restrict the immigration to only deserving and prevent the loop holes.
@dom_lucre@CyberGreen09 Work hard and qualify, opportunities aren’t restricted. Many immigrants succeed because they bring skills and effort. It’s a merit-based system. My doctor is Indian and excellent. The U.S. thrives on assimilation, don’t lose that.
@CueBiopharma@LifeSciEvents what a joke.....this is second CEO that left Cue in last one year.....add to this list a CMO, CSO, CFO that left the organization too. I don't know what are they doing...lost a whole lot on them.
@CueBiopharma Congratulations @CueBiopharma !! This is all good but investors want to know when is the IND. Can you please make a post regarding IND, your AI Indication etc. I might invest bit more then!!
@CueBiopharma@Boehringer@CueBiopharma I’d also be interested to hear Sidd’s perspective especially, how confident he is in the platform and why. Also, again when is the IND and FIH data availability date. You guys have great science but terrible communication.
@KRONIKInsights Education is important fuckers! Simply by knowing how to press the gas and brake doesn't make you a driver. India is pulled down by idiots like these and others who are busy taking the video instead of asking to slow it down. RIP
@back2earth21@DerickBores@CueBiopharma Looks like IND is approaching. Recent updates feel like positioning ahead of a meaningful catalyst. Market reaction is always uncertain, but successful execution here could be material. That said, capital structure considerations (incl. potential RS) shouldn’t be ignored.
@back2earth21@DerickBores@CueBiopharma Market sentiment is driving this. Prior management didn’t fully capitalize on the oncology assets. The new team is pivoting toward autoimmune indications a current investor favorite. In my view, it’s undervalued. Key catalyst: IND clearance and strong first-in-human data.
@DerickBores@CueBiopharma As a long-term biotech investor, I’m surprised they haven’t fully leveraged Sidd Srivastava. I’ve followed his execution for a decade, he knows how to advance programs and create value. When talent like that isn’t empowered, it says more about leadership than the science.
@LionPawMGT@EpicVideos__ I would do the same. There's no point in escalating; the other party is evidently unreasonable, anyway (based on the clip length, don't know what happened before or after).
@jurgen_nauditt As an American, I’d say this: if you truly believed India was insignificant, you wouldn’t be so worried about it. The fact that it’s keeping you up at night only shows how influential and consequential India has become, far more than you’re willing to admit.